394 related articles for article (PubMed ID: 19121979)
1. Allogeneic stem cell transplantation for severe aplastic anemia: graft rejection remains a problem.
Aki SZ; Sucak GT; Ozkurt ZN; Yeğin ZA; Yağci M; Haznedar R
Transfus Apher Sci; 2009 Feb; 40(1):5-11. PubMed ID: 19121979
[TBL] [Abstract][Full Text] [Related]
2. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
[TBL] [Abstract][Full Text] [Related]
3. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
[TBL] [Abstract][Full Text] [Related]
8. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
9. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.
Kim SY; Lee JW; Lim J; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Kim CC
Biol Blood Marrow Transplant; 2007 Jul; 13(7):863-70. PubMed ID: 17580265
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.
Storb R; Blume KG; O'Donnell MR; Chauncey T; Forman SJ; Deeg HJ; Hu WW; Appelbaum FR; Doney K; Flowers ME; Sanders J; Leisenring W
Biol Blood Marrow Transplant; 2001; 7(1):39-44. PubMed ID: 11215697
[TBL] [Abstract][Full Text] [Related]
11. Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.
McGuinn C; Geyer MB; Jin Z; Garvin JH; Satwani P; Bradley MB; Bhatia M; George D; Duffy D; Morris E; van de Ven C; Schwartz J; Baxter-Lowe LA; Cairo MS
Pediatr Blood Cancer; 2014 Jul; 61(7):1289-94. PubMed ID: 24623601
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
14. Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.
Azuma E; Kojima S; Kato K; Matsuyama T; Yamada Y; Kondo N; Sawada H; Hanada M; Shibata T; Tabata N; Watanabe M; Shimono Y; Deguchi T; Umemoto M; Higashikawa M; Kawasaki H; Komada Y; Sakurai M
Bone Marrow Transplant; 1997 Jun; 19(11):1085-7. PubMed ID: 9193750
[TBL] [Abstract][Full Text] [Related]
15. HLA-matched sibling stem cell transplantation in children with β-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience.
Goussetis E; Peristeri I; Kitra V; Vessalas G; Paisiou A; Theodosaki M; Petrakou E; Dimopoulou MN; Graphakos S
Bone Marrow Transplant; 2012 Aug; 47(8):1061-6. PubMed ID: 22080966
[TBL] [Abstract][Full Text] [Related]
16. Re-transplantation from the same unrelated donor in three adolescents with severe aplastic anemia after graft rejection.
Führer M; Claviez A; Klein B; Humpe A; Schrauder A
Klin Padiatr; 2009; 221(6):358-61. PubMed ID: 19890787
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
Bacigalupo A; Locatelli F; Lanino E; Marsh J; Socié G; Maury S; Prete A; Locasciulli A; Cesaro S; Passweg J;
Bone Marrow Transplant; 2005 Dec; 36(11):947-50. PubMed ID: 16205733
[TBL] [Abstract][Full Text] [Related]
18. A fludarabine-based conditioning regimen for severe aplastic anemia.
Chan KW; Li CK; Worth LL; Chik KW; Jeha S; Shing MK; Yuen PM
Bone Marrow Transplant; 2001 Jan; 27(2):125-8. PubMed ID: 11281379
[TBL] [Abstract][Full Text] [Related]
19. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
Okuda S; Terasako K; Oshima K; Sato M; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
Am J Hematol; 2009 Mar; 84(3):167-9. PubMed ID: 19195036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
